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Abstract Large sets of data and human specimens, such as
blood, tumour tissue and DNA, are deposited in biobanks for
research purposes, preferably for long periods of time and
with broadly defined research aims. Our research focuses on
the retention of data and biological materials obtained from
children. However important such paediatric biobanks may
be, the privacy interests of the children involved and the relat-
ed risks may not be ignored. The privacy issues arising from
paediatric biobanks are the central focus of this article. We
first review the international regulations that apply to
biobanks and then summarise viewpoints expressed by ex-
perts in a round-table discussion. We confine ourselves here
to two normative questions: (1) How much control should
children’s parents or legal representatives, and later the chil-
dren themselves, have over the stored materials and data? (2)
What should be done if research findings emerge that have
serious implications for a child’s health?
Conclusion: On the basis of international legal standards and
the views of experts, involved in paediatric biobanking, we
argue that biological material of children may only be stored
in a biobank for scientific purposes if parents provide their
explicit consent, the child is re-contacted at 16 or 18 years of
age to reconsider storage and use of its material, and the
biobank maintains a limited policy in disclosure of individual
research findings to the child’s parents.
What is Known:
• Increasingly, biological material of children is stored in biobanks for
research purposes.
•Clear standards on the conditions under which children’s cells or tissues
may be stored and used are lacking.
What is New:
• According to experts, storage and use of children’s materials should
only be allowed if performed in accordance with appropriate consent
procedures and feedback policies.
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Introduction
Collections of health data and human biological materials
(such as urine, blood and other tissues) are increasingly
required for scientific research in medicine in general.
Main reason for this is formed by the progress in technol-
ogy such as next generation sequencing which allows
studying large numbers of samples for biomarkers and
other characteristics that are important in basic research
and management. The samples are stored for long periods
of time in biobanks as this will allow using samples re-
peatedly over time, which is especially important if sam-
ples can be obtained only infrequently, typically because
the disorder is rare or obtaining samples is infrequently
possible. The Royal Dutch Academy of Arts and
Sciences defines a biobank as ‘a collection of human bio-
logical materials, compiled for scientific or treatment pur-
poses, with linkages to medical, genetic, genealogical or
other data about the donors. Biobank data and materials
may be, but are not necessarily, stored in the same loca-
tion. A biobank may therefore also be described as a chain
of action consisting of the collection, preparation, storage
and use of biological material and personal data’ [23].
There are various types of biobanks. They may differ ac-
cording to the type of materials they store and the ways they
acquire the materials. Two ways of acquisition can be distin-
guished: samples may be taken from human beings for the
specific purpose of scientific research and samples may be
obtained via clinical laboratories after analysis for care pur-
poses (‘residual materials’). Another distinction is whether
materials are stored in an anonymised, coded, or directly iden-
tifiable manner. Few biobanks store completely anonymous
materials, as most research requires establishing correlations
between samples and other data from participating subjects. If
samples and data are stored in an identifiable form (whether
coded or non-coded), it is also possible to disclose relevant
medical findings to the donors involved.
Although biobanks are vital to health care innovation
and improvement, the prolonged storage of personal bio-
logical samples entails risks to the individuals involved [2,
10, 13]. Human biological samples may serve a wide range
of research purposes, but purposes and their potential re-
sults are frequently not known at the time the samples are
collected. Samples and data in biobanks contain privacy-
sensitive information on the participating donors not only
about their current medical condition, but also about their
possible health situation in the future. Annas and col-
leagues described DNA as ‘future diaries’, a source of
highly sensitive information in which an important part of
each participant’s unique future is inscribed [2]. Data may
also have implications for family members. Information in
unauthorised hands or used for improper purposes may lead
to discrimination and stigmatisation. If sensitive informa-
tion obtained from samples, such as vulnerability to a seri-
ous genetic disorder, disclosure of such information could
trigger psychological distress and hamper access to re-
sources such as insurance or employment [19].
Biobanking samples from children is increasing even more
rapidly than biobanking of samples of adults, as the percent-
age of disorders with a genetic background is higher in chil-
dren compared to that in adults [33]. Indeed several large scale
paediatric biobanks are now operating in the Netherlands,
such as the Amsterdam-Born Children and Their
Development Study (ABCD) [1] and the KOALA cohort
study [22].
Next to the general characteristics of biobanks, paediatric
biobanks face specific additional problems, such as the young
age of donors which prevent responsible decisions at the time
of sample collection, and change with age of their decision-
making capacity, also legally. The present article explores the
issue of how children’s autonomy and rights to privacy ought
to be safeguarded when samples are deposited in a research-
oriented biobank. Their rights are initially exercised by their
legal representatives and later by the children themselves. A
considerable lack of clarity still exists on these matters in
biobank practice.We shall focus in particular on two questions
that have attracted much attention in literature [11, 13, 18, 21,
30]. The first is the right to decide about biobank participation:
what rights do a child’s legal representatives have to control
whether the child’s samples will be stored in a biobank, and
what rights does that child later have upon reaching the legal
age of decision-making capacity? The second question con-
cerns how individual research findings are to be dealt with:
should these be reported to the child in question (or to a legal
representative) in cases findings have implications for the
health of the child or of family members? After describing
the methods we used in our study (BUsed methods^ section),
we summarise the rules and standards that can be derived from
the international legal framework with respect to these two
questions (BInternational legal framework^ section). Then
the experts’ viewpoints, as expressed during a round-table
discussion, are discussed (BDiscussing legal standards with
experts^ section). Taking the latter into account, we suggest
a set of principles for paediatric biobanking (BTowards
concrete legal standards for banking children’s tissue^ sec-
tion) and close with a few final remarks (BConcluding
remarks^ section).
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Used methods
We performed a literature search using the electronic data-
bases PubMed, Westlaw International and HeinOnline to se-
lect relevant legal documents and literature, using combina-
tions of the following terms: (child OR children OR paediatric
OR pediatric), (biobank OR biobanks OR biobanking), (in-
formed consent), (individual findings OR individual results
OR incidental findings), (tissue OR biological material), (right
to know OR right not to know). The search was restricted to
documents in English and Dutch.
Furthermore, we organised a round-table discussion in order
to obtain the standards that according to Dutch experts should
apply to paediatric biobanks. We aimed to attract participants
with their expert knowledge of paediatric biobanking in
practice-level or policy-level experience, and participants with
a varying background in discipline and profession, including
paediatrics, clinical genetics, law and ethics, scientific research
and biobankmanagement and policy. Also, a representative of a
patient organisation was attracted. We invited 23 experts, of
which 11 were unable to be present due to work-related or
personal obligations. Twelve experts, working in medical insti-
tutes or academic medical centres located in different regions of
the Netherlands, were present at the meeting (Table 1) [24]. In
preparation of the round-table discussion, we formulated nine
normative starting points on the basis of earlier empirical find-
ings, scholarly literature and legal documents related to paedi-
atric biobank research [25]. These starting points were submit-
ted to the experts in advance and were discussed at the meeting
one by one to allow experts to express their in-depth views. The
organisers of the meeting did not participate themselves in the
debate between the invited experts. The discussion was tape-
recorded and transcribed verbatim. The key conclusions of the
meeting are summarised in paragraph 4. The topics to discuss
are available as Supplementary material (Table 2). We would
like to stress that the findings of the round-table meeting cannot
be seen as fully representative for the whole field of profes-
sionals involved in paediatric biobanking. However, the meet-
ing gave us a better picture of what experts involved in research
and biobank practice regard as appropriate and well-balanced
legal standards in this respect. On the basis of the findings, we
were able to reflect on our own, previously formulated, starting
points and redefine them as a set of principles for paediatric
biobanking.
International legal framework
First, by far the most important international document is the
Convention on Human Rights and Biomedicine (CHRB) from
the Council of Europe (1997) [8]. This convention stipulates
that storage and use of residual samples may take place only if
appropriate information and consent procedures have been fully
observed. It is important to note, however, that ‘… sometimes,
it will not be possible, or very difficult, to find the persons
concerned again in order to ask for their consent. In some cases,
it will then be sufficient for a patient or his or her representative,
who have been duly informed (for instance, bymeans of leaflets
handed to the persons concerned at the hospital), not to express
their opposition (italics: EJK, RCH,MCP)’. In accordance with
article 5 and 6 of this convention and the (non-binding)
International Declaration on Human Genetic Data, free and
informed consent to storage of a child’s residual samples should
be authorised by the child’s parents or representatives [8, 32].
Another significant provision of the Biomedicine Convention is
that it affirms people’s ‘right to know’ any information collect-
ed about their personal health, as well as their ‘right not to
know’ (that is, not to be informed of such information if they
do not wish to obtain it). Those rights are not absolute and may
be overruled in case of vital interest of donors or their relatives
(paragraph 70 CHRB Explanatory report) [7].
Table 1 Main characteristics of
participating experts Disciplinairy background
experts (n = 12)
n Institution
Donor Patient representative 1 Not applicable
Manager Biobank manager 1 Academic Medical Center Amsterdam
Physician Paediatrician 1 University Medical Center Groningen
Clinical geneticist 4* Academic Medical Center Amsterdam / Radboud
University Medical Center/Maastricht University
Medical Center / University Medical Center Utrecht
Physician-researcher-chair
institutional review board
1 Academic Medical Center Amsterdam
Expert Ethicist 2 University Medical Center Rotterdam/Maastricht
University Medical Center
Lawyer 2 Academic Medical Center Amsterdam/Ministry
of Health, Welfare and Sport
*One of the geneticists was also representing the Dutch Society of Clinical Genetics (VKGN)
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Second the Organisation for Economic Co-operation and
Development (OECD) Guidelines on Human Biobanks and
Genetic Research Databases (HBGRD) [26] devotes but little
attention to the status of children when they reach an age at
which they are in principle deemed capable of decision-
making or are granted that legal right if their material is still
being stored in a biobank. However, paragraph 45 of the
CHRB Explanatory Report does note that the opinions of
minors should carry increasing weight in decisions in keeping
with their age and maturity. A similar principle, affirming
children’s right to express their own opinions, is articulated
in article 12.1 of the United Nations Convention on the Rights
of the Child (UNCRC): ‘States Parties shall assure to the child
who is capable of forming his or her own views the right to
express those views freely in all matters affecting the child, the
views of the child being given due weight in accordance with
the age and maturity of the child’ [31]. The OECD guidelines
specifically state that consent for continued sample storage
and use should be obtained from minors once they gain the
capacity to decide according to applicable law or ethical prin-
ciples (annotation 32) [26].1 A comparable principle is pro-
posed by the Public and Professional Policy Committee
(PPPC) of the European Society of Human Genetics
(ESHG). The PPPC underlined the importance of allowing
young donors to renew or withdraw consent [18].
On the basis of the foregoing, the following general
framework can be outlined: (1) In principle, residual bio-
logical materials and data from children may be deposited
for research in biobanks only if their parents or legal rep-
resentatives have consented to the storage on the basis of
adequate information. (2) The information should include
details for the parents about how individual research find-
ings are to be dealt with and their opportunity to exercise,
on behalf of themselves and the child, the right not to
know about such findings. (3) Children at a certain age
may also exercise full or partial rights of decision with
respect to the retention or continued storage of their ma-
terials in a biobank and the disclosure of individual re-
search findings.
Discussing legal standards with experts
Informed consent
The first issue addressed was whether the requirement for
explicit, general consent from the parents or legal representa-
tives of a young, not yet competent donor is an appropriate
means of control over human specimens deposited in paedi-
atric biobanks. Some participants felt that such a requirement
was disproportionate, arguing that all patients treated in uni-
versity hospitals should be aware that scientific research may
be performed on their biological materials. Others believed the
requirement was defensible or that it depended on the circum-
stances. ‘The modalities make a big difference in practice.
When you’re talking about consent, you have to look at other
aspects of the situation too. How does the biobank work? Are
the biological materials anonymous or not? How long will
they be kept? Can information be disclosed to the donors?
Do they have options on whether or not to be informed about
certain things? Whether general consent is acceptable also
depends on those aspects’ (legal expert).
Consensus was ultimately reached on the standpoint that
long-term storage and use of identifiable residual samples
from young donors should in principle be allowed only if
the donors’ legal representatives have explicitly consented.
In that way, it is best guaranteed that parents can make con-
scious and responsible decisions about their child’s biobank
participation and all the different aspects involved [5, 11, 15,
16]. The experts argued for a concept of ‘generic’ consent,
indicating that the parents’ authorization would apply not to
a specific research question, but to a particular disease do-
main. As one expert put it, ‘If you were to get too specific
when you ask for consent, you could run into big problems,
because you’d have to re-contact the people every time you
want to take a further step in your research. That would be an
enormous obstacle’ (clinical geneticist).
All experts emphasised that clear information to parents is
an essential element of an appropriate consent procedure.
Specific guidelines were considered necessary, requiring that
information be provided in any case on the type of biobank
involved, the period of sample retention and the policy on
individual findings. Information provided orally could be sup-
ported by an information leaflet.
The international legal framework, as described in the
BInternational legal framework^ section, leaves room for var-
ious consent systems and therefore allows for both explicit
and implicit consent systems, and systems that allow
exceptions.
Subsidiarity principle
The need to comply with the subsidiarity principle was also
underlined during the round-table discussion, whereby chil-
dren’s samples are to be retained only if they are essential to
the purpose of the biobank in question. As one expert argued:
‘That principle always applies, in fact. Specimens should only
be put in a biobank for things that can be studied only with
biological materials from that particular category of people’
(clinical geneticist).
1 See furthermore Article 15 of Council of Europe’s Recommendation
R(2006)4 on Research on biological materials of human origin, which stipu-
lates that children must be enabled to exercise their rights as soon as they attain
the capacity to provide consent. Included are the rights to withdraw or alter the
scope of consent given by parents on their behalf [9].
78 Eur J Pediatr (2017) 176:75–82
Child’s right to withdraw
Reservations were aired about the rule enabling children to
decide for themselves from age 12 about retention of their
samples in biobanks. A joint decision by parents and adoles-
cents seemed more appropriate up to an age of 16 or 18, with
independent decisions thereafter. Though a slight preference
was apparent for age 18, no clear consensus emerged from the
discussion as to the exact age at which donors should decide
independently about biobank retention of their samples.
Disclosure of individual findings
Another main topic treated in the expert meeting was how
individual findings should be dealt with, should they emerge
during scientific research. Since non-clinical medical research
focuses on groups rather than on individuals, typically re-
searchers are not looking actively for individual findings,
but theymay encounter such findings [27]. The experts agreed
that parents and/or children must be informed of any informa-
tion of a life-saving nature. As one clinical geneticist
remarked, ‘If you run into something in your lab and you know
it has individual consequences for the patient involved and
that I can avert something terrible by telling them, then I don’t
think you can expect researchers to keep it to themselves’
(clinical geneticist). Participants warned for a misunderstand-
ing of the term ‘duty to warn’, often used in this context,
because it suggests a legal duty whereas it merely involves a
moral one. In their view biobank, researchers should be aware
of the fact that they have a professional moral responsibility to
notify the child’s representatives in case of a clear threat to the
health of their child.
They pointed to the need to distinguish between contexts in
which researchers are at the same time the health care pro-
viders of the study participants and those in which they are
not. A conservative disclosure policy would suffice in the
latter situation. The moral obligation of researchers for early
detection and notification applies in particular to findings that
are of immediate, unmistakable importance to the donor’s
state of health and for which realistic therapeutic or preventa-
tive options are indicated. In the literature, views have been
expressed that either concur [2, 3, 18] or diverge, with some
authors advocating more qualified disclosure policies where-
by donors may specify what they do and do not wish to be
informed about [4]. According to the experts, a researcher
who is also the donor’s health care provider will have to take
the legal duty of care for the patient into account as well.
Whereas researchers, not being the donor’s health care pro-
vider, do not have individual contact with the donor, health
care providers do have a treatment relationship. This implies
that they have a legal obligation to act according to profes-
sional standards, i.e. the duty to take good care of their patient.
The latter means, e.g. that findings, resulting from research
should be reported to the donor or to the parents even if these
do not clearly meet the criteria of immediate health risk and
being actionable.
One expert emphasised the importance of clearly commu-
nicating in patient information materials which types of find-
ings might be disclosed, so that donors or parents are well
aware of what they may and may not expect and have no
wrong expectations [14, 20, 29]. Several participants pointed
out that the decision of whether or not to disclose of findings
to donors or parents is the responsibility of health care pro-
viders and not of researchers. The role of the former as care
providers enables them to judge best the ways and extends to
inform patients.
Parental right to know and not to know
The next topic was what the parents’ rights to know and not to
know should actually entail in relation to research findings
made on their children younger than age 12. One expert cau-
tioned that ‘this is an awkward issue. Shouldn’t parents just be
allowed to know everything? No, wait, ... parents aren’t
allowed to stay ignorant of information that’s vital to their
child, so by the same token they shouldn’t be able to find out
everything’ (ethicist).
Consensus was ultimately reached: the information provid-
ed to parents should not extend the clinically actionable im-
mediate health risks that must be disclosed to donors under the
duty to warn. In principle, this means that for instance infor-
mation about late onset health conditions or about reproduc-
tive choices should not be disclosed to parents. The interests
of the child ought to be the deciding factor.
The international legal framework does not provide addi-
tional guidance: it mentions that the right to know and not to
know should be properly implemented in nationals laws and
regulations. What role parents (who may have their own in-
terests in knowing or not knowing) should play in that process
is left to national discretion. The PPPC emphasised that the
potential benefit of children to know actionable findings rele-
vant to their health should prevail over the parental right not to
know [18].
Donors’ rights when reaching the age of decision-making
capacity
The expert group discussed the rights of donors who reach the
legal age of decision-making capacity while their biological
material is still stored in a biobank. Although it is clear from
the legal documents that children ought to be given some say
as they grow older about whether their samples may be
retained and whether they wish to be informed, it cannot be
precisely determined at what age those rights may be
exercised and to which type of donor control (opt-out or
explicit consent) they are entitled. Should biobanks, when
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donors obtain the competence to decide on these matters (un-
der Dutch law: at the age of 12) simply be required to inform
them, or should they actually have to obtain their explicit
consent for continued storage and use? The experts judged
the latter option as unreasonable. They did not consider ado-
lescents sufficiently capable of deciding about biobank partic-
ipation until 16 or 18 years of age. A similar view has been
expressed in literature [6, 10, 12, 17, 27, 28]. Consequently,
they argued that donors should not be asked to consent to
continued storage and use until then. They also felt that the
consent requirement for adolescents approaching adulthood
should not be absolute; exceptions to the requirement should
be possible in certain cases, as when very large groups of
donors are involved or donors cannot be tracked down or
are diseased [12].
It was agreed that a general information letter to donors and
their parents is necessary when a child reaches the age of
decision-making capacity. One suggestion was ‘perhaps to
send 12-year-olds a card saying, BHappy birthday! By the
time you turn 18, we shall....^’ (physician-researcher-chair
institutional review board). Experts proposed that decision-
making by the donors could be facilitated by a website offer-
ing clear information about the storage and use of their sam-
ples, which could be brought under their attention. Notably,
the Dutch legal framework permits children aged 12 and older
to exercise the right to object to the use of their samples inde-
pendently, unless they are incompetent to take well-founded
decisions. The experts, however, all felt it would go too far to
actively inform 12-year-old children about their rights since
the matter was seen to be too complex for people of that age to
form a good opinion. At the same time, they acknowledged
the importance of easily accessible information for young do-
nors and concluded that any special requests from children of
that age to terminate their participation should in principle be
honoured.
Towards concrete legal standards for banking
children’s tissue
Parental right to decide about participation
We re-iterate as first principle that biological samples of in-
fants or young children may be deposited in a research-
oriented biobank only if the parents have given their explicit
informed consent. This principle is articulated in international
regulations and is fully endorsed by the expert meeting. The
persuasive argument for an explicit-consent procedure is that
opt-out procedures do not guarantee that parents are aware of
storage and storage circumstances of the residual samples of
their children, including major issues such as goals of storage,
consequences, potential risks and the voluntary nature of
sample donation [24].
We conclude from legal guidelines described in paragraph
3 and the experts’ opinions that children 12 years of age are
too young tomake a well-founded appraisal of continuation or
not of storage of samples in a biobank. Children should be at
least 16 to decide independently of its parents about this. The
Dutch legislative framework permits adolescents aged 16 and
older in principle to decide independently about their treat-
ment and, after acceptance of an amendment bill, about par-
ticipating in biomedical research.
That children under 16 do not yet qualify for independent
consent does not mean, of course, that they do not need to be
informed about their participation and should not be involved in
the decision-making process. Indeed, they ought to be engaged
in the decision by their parents as fully as possible and in keep-
ing with their comprehension abilities. If children then object to
biobank participation, their wishes ought to be respected, pro-
vided they are deemed capable of making a reasonable decision
about the issue. We recall that all experts are Dutch and there-
fore are familiar with the Dutch legal system which provides
fixed age-thresholds for decision-making by the child.
Following the experts’ views, three qualifications need to be
made with regard to the principle of explicit informed consent.
First, in paediatric biobanking, the consent must be generic
rather than specific in nature. This implies that the consent does
not apply to a specific research question or research protocol.
However, consent should be preferably confined to a particular
disease domain (i.e. cancer or cardiovascular diseases), be-
cause, in that way, the principle of self-determination of young
children, who cannot express their own views the moment their
material is stored in a biobank, is respected as much as possible.
Besides, the donors and their representatives are at least roughly
informed about the broader future research goals. Second, un-
derstandable informationmust be provided through an effective
website and information leaflet which clearly describes the key
characteristics of the biobank, its policies on disclosures of
individual research findings and the rights of the child (as
exercised by the legal representatives until the child is able to
decide independently about participation). Third, exceptions to
the consent principle ought to be possible in certain situations;
this applies in particular to the requirement to re-contact donors
aged 16 whose biological materials were deposited in a biobank
at young ages, since such adolescents may now no longer be
traceable [24].
Dealing with individual research findings
Existing international legal documents provide no more than a
general framework for acting on research findings that could
be vital to individual patients or donors or to their family
members. Researchers are to report any important health in-
formation they encounter (the right to know), but they are also
to respect requests from donors or their parents not to be
informed (the right not to know). Neither of these rights is
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absolute; however; they may be restricted in certain circum-
stances. With respect to disclosure of individual research find-
ings encountered by researchers, we conclude that, at the min-
imum, findings that signal a life-threatening situation or seri-
ous health detriment for a child, and for which therapeutic or
preventative measures are available, are to be reported to the
parents and/or the child. This indicates that those findings are
not communicated which presage health conditions that are
not actionable, especially those that are unlikely to manifest
themselves until adult age.
We agree with the experts that a limited disclosure obliga-
tion would be the most appropriate, whereby findings would
be reported to parents only if they are deemed important and
clinically actionable. That would allow no leeway for parents
to determine which types of findings they do or do not want to
know. A key argument for such a policy is that biobanks do
not store samples for the purpose of diagnosing patients
(which is the task of a health care provider), but for the pur-
pose of knowledge enhancement. From that standpoint, dis-
closure of individual findings made in scientific research
should be an exception. It is therefore important that parents
not have misleading expectations when they consent to have
their children’s samples deposited in biobanks [24].
Concluding remarks
On the basis of the here presented results of the international
legal document analysis and the round-table discussion with
experts from a wide range of disciplines, we formulated a set
of principles that may be useful for professionals, involved in
paediatric biobanking. However, we want to stress that there
are still several issues in this field we did not address in our
research and which need further attention and exploration. To
name a few: Does the researcher’s responsibility towards do-
nors include tracing back the donor in case actionable findings
emerge, even years after storage of the material? What if, after
some time, previously non-actionable findings turn into high-
ly actionable ones? Do researchers have an obligation to
screen their data in light of new scientific insights and to look
for actionable findings, and if so, in what frequency? Such
issues should certainly be part of future research about
(paediatric) biobanking.
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